DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Pivot X, Romieu G, Debled M. et al
PHARE trial investigators. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Lancet 2019;
393 (10191) 2591-2598
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.